Immunic Stock Forecast, Price & News

-0.59 (-3.94 %)
(As of 04/12/2021 02:42 PM ET)
Today's Range
Now: $14.38
50-Day Range
MA: $15.71
52-Week Range
Now: $14.38
Volume3,991 shs
Average Volume231,930 shs
Market Capitalization$304.40 million
P/E RatioN/A
Dividend YieldN/A
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Immunic logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMUX
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$5.77 per share


Net Income$-34,930,000.00


Market Cap$304.40 million
Next Earnings Date5/14/2021 (Estimated)
OptionableNot Optionable


Immunic, Inc. (NASDAQ:IMUX) Short Interest Update
March 31, 2021 |
Immunic (NASDAQ:IMUX) Coverage Initiated at JMP Securities
March 24, 2021 |
Form 10-K IMMUNIC, INC. For: Dec 31 -
February 26, 2021 |
Form 8-K IMMUNIC, INC. For: Feb 26 -
February 26, 2021 |
Form 8-K IMMUNIC, INC. For: Feb 17 -
February 19, 2021 |
See More Headlines


Overall MarketRank

1.55 out of 5 stars

Medical Sector

444th out of 2,011 stocks

Pharmaceutical Preparations Industry

214th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
-0.59 (-3.94 %)
(As of 04/12/2021 02:42 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMUX News and Ratings via Email

Sign-up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Immunic (NASDAQ:IMUX) Frequently Asked Questions

Is Immunic a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Immunic stock.
View analyst ratings for Immunic
or view top-rated stocks.

What stocks does MarketBeat like better than Immunic?

Wall Street analysts have given Immunic a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immunic wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Immunic?

Immunic saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 931,800 shares, a drop of 28.9% from the February 28th total of 1,310,000 shares. Based on an average trading volume of 265,200 shares, the short-interest ratio is presently 3.5 days.
View Immunic's Short Interest

When is Immunic's next earnings date?

Immunic is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Immunic

How were Immunic's earnings last quarter?

Immunic, Inc. (NASDAQ:IMUX) issued its quarterly earnings data on Friday, February, 26th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.13.
View Immunic's earnings history

How has Immunic's stock price been impacted by COVID-19 (Coronavirus)?

Immunic's stock was trading at $7.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IMUX shares have increased by 85.5% and is now trading at $14.38.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IMUX?

9 Wall Street analysts have issued 12 month price targets for Immunic's stock. Their forecasts range from $45.00 to $71.00. On average, they anticipate Immunic's stock price to reach $58.38 in the next year. This suggests a possible upside of 305.9% from the stock's current price.
View analysts' price targets for Immunic
or view top-rated stocks among Wall Street analysts.

Who are Immunic's key executives?

Immunic's management team includes the following people:
  • Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A, Exec. Chairman (Age 50, Pay $519.54k)
  • Dr. Daniel Vitt, CEO, Pres & Director (Age 53, Pay $381.62k)
  • Dr. Manfred Gröppel, Co-Founder & COO (Age 52, Pay $193.64k)
  • Dr. Andreas Muehler Ph.D., M.D., Chief Medical Officer (Age 55, Pay $269.06k)
  • Mr. Glenn Whaley, VP of Fin. and Principal Financial & Accounting Officer (Age 53)
  • Dr. Hella Kohlhof, Chief Scientific Officer (Age 48)
  • Jessica Breu, Head of Investor Relations & Communications

Who are some of Immunic's key competitors?

What other stocks do shareholders of Immunic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY), NIO (NIO), NVIDIA (NVDA), TG Therapeutics (TGTX) and Ampio Pharmaceuticals (AMPE).

What is Immunic's stock symbol?

Immunic trades on the NASDAQ under the ticker symbol "IMUX."

How do I buy shares of Immunic?

Shares of IMUX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunic's stock price today?

One share of IMUX stock can currently be purchased for approximately $14.38.

How much money does Immunic make?

Immunic has a market capitalization of $304.40 million. The company earns $-34,930,000.00 in net income (profit) each year or ($4.52) on an earnings per share basis.

How many employees does Immunic have?

Immunic employs 28 workers across the globe.

What is Immunic's official website?

The official website for Immunic is

Where are Immunic's headquarters?

Immunic is headquartered at 1200 AVENUE SUITE 200, NEW YORK NY, 10036.

How can I contact Immunic?

Immunic's mailing address is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. The company can be reached via phone at 332-255-9818 or via email at [email protected]

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.